FindTrial
Sign In

Aromatase Inhibitor (AI)

DRUG5 trials

Sponsors

Eli Lilly and Company, Tvardi Therapeutics, Incorporated, Peking University Cancer Hospital & Institute, Hebei Medical University Fourth Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions

Advanced Breast CancerBreast CancerEarly-Stage Breast CancerEndometrial CancerHER2 Low Breast CarcinomaHormone Receptor-Positive Breast CancerMetastatic Breast Cancer

Phase 1

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Active, not recruitingNCT04188548
Eli Lilly and CompanyBreast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer +1
Start: 2019-12-10End: 2027-12-01Updated: 2026-06-22
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
TerminatedNCT05384119
Tvardi Therapeutics, IncorporatedBreast Cancer
Start: 2023-01-09End: 2024-04-25Updated: 2025-02-21

Phase 2

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Not yet recruitingNCT07527806
Peking University Cancer Hospital & InstituteBreast Cancer
Start: 2026-05-01End: 2029-12-31Target: 156Updated: 2026-04-17
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy
Not yet recruitingNCT07782840
Hebei Medical University Fourth HospitalBreast Cancer
Start: 2026-10-01End: 2028-12-01Target: 40Updated: 2026-08-26
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Not yet recruitingNCT07796880
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer
Start: 2026-09-15End: 2033-03-15Target: 80Updated: 2026-09-10

Related Papers

Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.
Journal of Clinical Oncology2024-06-012 citations
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.
Journal of Clinical Oncology2024-06-01
Abstract PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
Cancer Research2024-05-022 citations
51P ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study
ESMO Open2024-05-01
Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study
Cancer Research2023-03-0111 citations
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
Journal of Clinical Oncology2022-06-0138 citations
Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)
Cancer Research2021-07-0128 citations
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.
Journal of Clinical Oncology2021-05-2036 citations
Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer
Cancer Research2021-02-159 citations